Journal for ImmunoTherapy of Cancer

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
Minyu Wang, Soroor Zadeh, Angela Pizzolla, Kevin Thia, David E Gyorki, Grant A McArthur, Richard A Scolyer, Georgina Long, James S Wilmott, Miles C Andrews, George Au-Yeung, Ali Weppler, Shahneen Sandhu, Joseph A Trapani, Melissa J Davis, Paul Joseph Neeson

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004095; DOI: 10.1136/jitc-2021-004095
Correction: Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e001580corr1; DOI: 10.1136/jitc-2020-001580corr1
Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment
Dali Tong

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e002944; DOI: 10.1136/jitc-2021-002944
Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e003289corr1; DOI: 10.1136/jitc-2021-003289corr1
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Yoon-Koo Kang, Martin Reck, Paul Nghiem, Yan Feng, Gregory Plautz, Hye Ryun Kim, Taofeek K Owonikoko, Narikazu Boku, Li-Tzong Chen, Ming Lei, Han Chang, Wen Hong Lin, Amit Roy, Akintunde Bello, Jennifer Sheng

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004273; DOI: 10.1136/jitc-2021-004273
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8⁺ T cell cytotoxicity over BEMPEG+RT
Annah S Rolig, Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L Redmond

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004218; DOI: 10.1136/jitc-2021-004218
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert Andtbacka, Jun Guo

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004307; DOI: 10.1136/jitc-2021-004307
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
Yanchen Zhou, Hweixian L Penny, Mark A Kroenke, Bianca Bautista, Kelly Hainline, Lynette S Chea, Jane Parnes, Daniel T Mytych

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004225; DOI: 10.1136/jitc-2021-004225
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Haizhou Wang, Yabo Zhou, Yangyang Zhang, Shilin Fang, Meng Zhang, Haiou Li, Fei Xu, Lan Liu, Jing Liu, Qiu Zhao, Fan Wang

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004302; DOI: 10.1136/jitc-2021-004302
Correction: Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e000960corr1; DOI: 10.1136/jitc-2020-000960corr1

Main menu

Journal for ImmunoTherapy of Cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Journal for ImmunoTherapy of Cancer

Pages